Liquid biopsy can 'personalise' therapy for colon cancer

A randomised trial in Australia shows use of the test reduces adjuvant chemotherapy without increasing cancer recurrence

A liquid biopsy-guided approach to treating stage II colon cancer can reduce reliance on adjuvant chemotherapy without jeopardising patient survival, a pivotal study suggests.

Melbourne-led authors say results from the DYNAMIC trial could further personalise oncological care, with the decision to treat predicated on presence of circulating tumour DNA (ctDNA).

Prior studies of localised colon cancer have consistently shown that ctDNA testing can reliably detect minimal residual disease post-surgery and